Literature DB >> 23964037

Acute respiratory failure secondary to mesalamine-induced interstitial pneumonitis.

Albin Abraham1, Ali Karakurum.   

Abstract

Interstitial pneumonitis as an adverse effect of mesalamine therapy is a rare but potentially serious complication. Patients typically have a mild disease course with no documented cases of respiratory failure in published literature. Given its variable latent period and non-specific signs and symptoms, it may be difficult to diagnose. We present the case of a 65-year-old man who presented with symptoms of fever, shortness of breath and a non-productive cough, 2 weeks after initiation of therapy with mesalamine. His hospital course was complicated by acute respiratory failure requiring intubation and mechanical ventilation. Radiographic studies revealed bilateral lower lobe infiltrates and bronchosopy with bronchoalveolar lavage and transbronchial biopsy were consistent with a diagnosis of drug-induced interstitial pneumonitis. The aim of this paper is to highlight the importance of considering a diagnosis of mesalamine-induced lung injury in patients presenting with respiratory symptoms while on mesalamine therapy and to review relevant literature.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23964037      PMCID: PMC3761449          DOI: 10.1136/bcr-2013-009834

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  17 in total

1.  Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences.

Authors:  Edward V Loftus
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

2.  Lung disease associated with orally administered mesalamine for ulcerative colitis.

Authors:  M A Reinoso; K W Schroeder; R J Pisani
Journal:  Chest       Date:  1992-05       Impact factor: 9.410

3.  Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000.

Authors:  Conor G Loftus; Edward V Loftus; W Scott Harmsen; Alan R Zinsmeister; William J Tremaine; L Joseph Melton; William J Sandborn
Journal:  Inflamm Bowel Dis       Date:  2007-03       Impact factor: 5.325

Review 4.  Can a drug-induced pulmonary hypersensitivity reaction be dose-dependent? A case with mesalamine.

Authors:  P Sossai; M G Cappellato; S Stefani
Journal:  Mt Sinai J Med       Date:  2001-11

Review 5.  Current treatment of ulcerative colitis.

Authors:  Johannes Meier; Andreas Sturm
Journal:  World J Gastroenterol       Date:  2011-07-21       Impact factor: 5.742

Review 6.  Mesalamine-induced lung toxicity.

Authors:  A Bitton; M A Peppercorn; J P Hanrahan; M P Upton
Journal:  Am J Gastroenterol       Date:  1996-05       Impact factor: 10.864

7.  Mesalazine: a global safety evaluation.

Authors:  R Brimblecombe
Journal:  Scand J Gastroenterol Suppl       Date:  1990

Review 8.  The lung in inflammatory bowel disease.

Authors:  P Camus; F Piard; T Ashcroft; A A Gal; T V Colby
Journal:  Medicine (Baltimore)       Date:  1993-05       Impact factor: 1.889

Review 9.  Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches.

Authors:  Osamu Matsuno
Journal:  Respir Res       Date:  2012-05-31

10.  Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine.

Authors:  Kavinderjit Nanda; Alan C Moss
Journal:  Clin Pharmacol       Date:  2012-07-25
View more
  4 in total

1.  Organizing pneumonia: a rare pulmonary manifestation of well-controlled ulcerative colitis.

Authors:  Xiaoming Zhou; Yu Chen; Li Zhao
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

2.  Gastroenterology case report of mesalazine-induced cardiopulmonary hypersensitivity.

Authors:  José Ferrusquía; Isabel Pérez-Martínez; Ricardo Gómez de la Torre; María Luisa Fernández-Almira; Ruth de Francisco; Luis Rodrigo; Sabino Riestra
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

Review 3.  Five-aminosalicylic Acid: an update for the reappraisal of an old drug.

Authors:  Cristiana Perrotta; Paolo Pellegrino; Eliana Moroni; Clara De Palma; Davide Cervia; Piergiorgio Danelli; Emilio Clementi
Journal:  Gastroenterol Res Pract       Date:  2015-01-21       Impact factor: 2.260

4.  Mesalazine-induced lung injury with severe respiratory failure successfully treated with steroids and non-invasive positive pressure ventilation.

Authors:  Hajime Oi; Atsushi Suzuki; Yasuhiko Yamano; Toshiki Yokoyama; Toshiaki Matsuda; Kensuke Kataoka; Yasuhiko Suzuki; Tomoki Kimura; Yasuhiro Kondoh
Journal:  Respir Med Case Rep       Date:  2020-08-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.